Pulse Biosciences, Inc. / Fundamentals
Income statement
- Net revenue
€716.81K - Cost of goods sold
€1.18M - Gross profit
-€460.07K - SG&A expenses
€26.88M - R&D expenses
€35.12M - EBITDA
-€60.55M - D&A
€730.59K - EBIT
-€62.23M - Interest expenses
€0.00 - EBT
-€58.61M - Tax expenses
€0.00 - Net income
-€58.61M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€779.70K - Changes in working capital
€3.05M - Operating cash flow
-€38.34M - Capex
€205.91K - Other investing cash flow
-€17.23K - Net investing cash flow
-€223.14K - Total cash dividends paid
€0.00 - Issuance of common stock
€51.36M - Debt repayment
€0.00 - Other financing cash flow
€107.31M - Net financing cash flow
€107.61M - Foreign exchange effects
€0.00 - Net change in cash
€69.06M - Cash at end of period
€91.62M - Free cash flow
-€38.13M
Balance sheet
- Cash and cash equivalents
€91.62M - Cash and short-term investments
€91.62M - Total receivables
€0.00 - Inventory
€43.94K - Other current assets
€1.52M - Total current assets
€93.19M - Property, plant & equipment
€6.65M - Goodwill
€2.40M - Intangible assets
€781.43K - Long-term investments
€0.00 - Other non-current assets
€583.27K - Total non-current assets
€10.42M - Total assets
€103.60M - Accounts payable
€2.36M - Short-term debt
€1.26M - Other current liabilities
€4.12M - Total current liabilities
€7.73M - Long-term debt
€5.85M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€5.85M - Total liabilities
€13.58M - Common stock
€57.72K - Retained earnings
-€367.42M - Other equity
€0.00 - Total equity
€90.02M - Total liabilities and shareholders' equity
€103.60M
Company information
- Market capitalization
€865.31M - Employees
75 - Enterprise Value
€1.01B
Company ratios
- Gross margin
-
-64.2% Much worse than peer group: 53.4% - EBITDA margin
-
-8,447.1% Much worse than peer group: 0.6% - EBIT margin
-
-8,682.1% Much worse than peer group: -5.4% - EBT margin
-
-8,176.4% Much worse than peer group: -114.7% - Net margin
-
-8,176.4% Much worse than peer group: -8.6% - ROE
-
-65.1% Much worse than peer group: 59.2% - ROA
-
-56.6% Much worse than peer group: -13.5% - Asset turnover
-
0.7% Much worse than peer group: 96.0% - FCF margin
-
-5,376.8% Much worse than peer group: -4.8% - FCF yield
-4.5% - Efficiency ratio
8,547.1% - Net sales per employee
-
€9.56K - Net income per employee
-
-€781.46K